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1. Introduction 
Melanin is one of the most important pigments which exist ubiquitously from 
microorganisms to plants and animals. It is secreted by melanocyte cells and determines the 
color of skin and hair in mammalians. It protects the skin from photocarcinogenesis by 
absorbing UV sunlight and removing reactive oxygen species (ROS) (Gupta, 2006; Kim, 
2005; Sapkota, 2011). It is formed by enzymatically catalyzed chemical reactions (Chang, 
2009). The modifications in melanin biosynthesis occur in many disease states. The excessive 
level of melanin pigmentation causes various dermatological disorders including 
hyperpigmentations such as senile lentigo, melasma, postinflammatory melanoderma, 
freckles, ephelide, age spots and sites of actinic damage which can give rise to esthetic 
problems (Briganti, 2003; Curto, 1999). Hyperpigmentation usually becomes a big problem 
as people age because darker spots will start to be seen on the face, arms and body. Also, 
hormonal changes such as pregnancy and drugs manipulating hormone levels may cause 
hyperpigmentation.  
Inhibitors of the enzyme tyrosinase (EC 1.14.18.1, syn.polyphenol oxidase, PPO; 
monophenol; dihydroxy-L-phenylalanin; oxidoreductase) can be used to prevent or treat 
melanin hyperpigmentation disorders. Therefore, they have become increasingly important 
in cosmetic and medical products. Besides being used in the treatment of some 
dermatological disorders associated with melanin hyperpigmentation, tyrosinase inhibitors 
are found to have an important role in cosmetic industry for their skin lightening effect and 
depigmentation after sunburn (Briganti, 2003; Chang, 2009; Khan, 2007; Parvez, 2007; Seo, 
2003). Tyrosinase  is a common multifunctional copper-containing enzyme from the oxidase 
superfamily found in plants, animals and fungi. It is responsible for melanin biosynthesis, 
which determines the color of skin, hair and fur.  It is at the moment a well-characterized 
enzyme. As an enzyme that produces pigment, tyrosinase catalyzes two key reactions in the 
melanin biosynthesis pathway: the addition of a hydroxyl group (-OH) to the amino acid 
tyrosine, which then becomes 3,4-dihydroxypheylalanine (L-DOPA). The tyrosinase enzyme 
then converts L-DOPA into o-dopaquinone by an oxidation reaction. Following these two 
main steps, melanin is then generated after further enzymatic steps (Scheme 1) (Gupta, 2006; 
Parvez, 2007). Melanin formation is considered to be deleterious to the color quality and 
flavor, and loss of nutritional and market values of foods. So, it causes the enzymatic 
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browning in fruits and vegetables. In the food industry, tyrosinase is important in 
controlling the quality and economics of fruits and vegetables. Hence, tyrosinase inhibitors 
from natural sources have great potential in the food industry, as they are considered to be 
safe and largely free from adverse effects. Also in insects, tyrosinase is involved in 
melanogenesis wound healing, parasite encapsulation and sclerotisation (Seo, 2003). 
Therefore, tyrosinase inhibitors used as insecticides and insect control agents. Moreover, the 
tyrosinase is responsible from melanization in animals and is the key enzyme for the 
regulation of melanogenesis in mammals. Melanogenesis is the process by which melanin is 
produced and subsequently distributed by melanocytes within the skin and hair follicles. 
This process results in the synthesis of melanin pigments, which play a protective role 
against skin photocarcinogenesis (Khan, 2007; Kim, 2005). 
 
Scheme 1. Biosynthetic pathway of melanin (Chang, 2009; Kim, 2005; Seo, 2003). DOPA, 3,4-
dihydroxyphenylalanine; DHI, 5,6-dihydroxyindole; DHICA, 5,6-dihydroxyindole-2-
carboxylic acid. 
Safety is a primary consideration for tyrosinase inhibitors, especially when utilized in 
unregulated quantities on a regular basis. On the other hand, the use of the inhibitors is 
primary in the cosmetic industry due to their skin-whitening effects. Since a huge number of 
tyrosinase inhibitors have been developed, assessing the validation of these inhibitors in 
skin-whitening efficiency has become more important. Most inhibitors have rarely been 
incorporated in topically applied cosmetics, often due to a lack of parallel human clinical 
trials (Chang, 2009; Khan, 2007; Kim, 2005). 
Compounds called inhibitors are being synthesized to hinder or completely stop the 
enzyme’s function. Natural products have already been discovered, experimented upon and 
proved to be safe and viable. However, due to depleting resources, synthetic derivatives 
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based on naturally occurring compounds have opened up this research to a broad range of 
possible tyrosinase inhibitors (Diaz, 2009). There are several inhibition mechanisms of 
tyrosinase but only two types’ inhibitors are regarded as “true inhibitors”. These are specific 
tyrosinase inactivators and specific tyrosinase inhibitors. Specific tyrosinase inactivators 
such as mechanism-based inhibitors are also called suicide substrates. These inhibitors can 
be catalyzed by tyrosinase and form covalent bond with the enzyme, thus irreversibly 
inactivating the enzyme during catalytic reaction. They inhibit tyrosinase activity by 
inducing the enzyme catalyzing “suicide reaction.” Specific tyrosinase inhibitors reversibly 
bind to tyrosinase and reduce its catalytic capacity (Chang, 2009). Therefore, the inhibition 
of tyrosinase is very essential in controlling the economy of foods and agriculture. 
Development of high-performance tyrosinase inhibitors is currently needed for these fields 
(Parvez, 2007).  
Mushroom tyrosinase is popular among researchers as it is commercially available and 
inexpensive. It plays a critical role in tyrosinase inhibitor studies for its use in cosmetics as 
well as in food industries, and many researches have been conducted with this enzyme, 
which is well studied and easily purified from the mushroom Agaricus bisporus. No matter in 
terms of inhibitory strength, inhibitory mechanism, chemical structures, or the sources of the 
inhibitors, the search for new inhibitors based on mushroom tyrosinase has been so 
successful that various different types of inhibitors have been found in the past 20 years 
(Chang, 2009; Parvez, 2007; Seo, 2003). 
In cosmetic products, tyrosinase inhibitors are used for skin-whitening effect, preventing 
formation of freckles and skin depigmentation after sunburn. Use of them is becoming 
increasingly important in the cosmetic and medicinal industries due to their preventive 
effect on pigmentation disorders. A number of tyrosinase inhibitors have been reported 
from both natural and synthetic sources, but only a few of them are used as skin-whitening 
agents, primarily due to various safety concerns, e.g. high toxicity toward cells, and low 
stability toward oxygen and water, resulting with their limited application (Chang, 2009; 
Kim, 2005). 
Inhibitors of tyrosinase enzyme have a huge impact on industry and economy. Therefore, 
researchers around the world are studying on the discovery of several classes of these 
inhibitors. Although a large number of tyrosinase inhibitors have been reported from both 
natural resources or semi- and full synthetic pathways, only a few of them are used as skin 
lightening agents, primarily due to various safety concerns. For example, kojic acid and 
catechol derivatives, well-known hypopigmenting agents, inhibit enzyme activity but also 
exhibit harmful side effects (Fig. 1) (Seo, 2003). 
Kojic acid (5-hydroxy-2-hydroxymethyl-4H-pyran-4-one) (Fig. 1, 4) and arbutin (4-
hydroxyphenyl--D-glucopyranoside), extracted from leaves of common bearberry, are 
often used in skin care products as a lightening agent (Fig. 1). It has been shown to be safe 
and effective for topical use (Burdock, 2001). Recently, bibenzyl analogues are reported to 
have potent anti-tyrosinase activity with almost 20-fold stronger than kojic acid. However, 
the inhibitory activity of kojic acid is not sufficiently potent or unstable for storage for use in 
cosmetics. Kojic acid, a well-known tyrosinase inhibitor, alone or together with tropolone 
and L-mimosine are often used as the positive control in the literature for comparing the 
inhibitory strength of the newly inhibitors (Briganti, 2003; Chang, 2009; Khan, 2007; Parvez, 
2007). L-mimosine, kojic acid and tropolone, having structural similarity to phenolic 
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subsrates and showing competitive inhibition with respect to these substrates, are known as 
slow binding inhibitors (Seo, 2003). In addition, most tyrosinase inhibitors listed below are 
not currently commercially available, especially those from natural sources, and this limits 
their further evaluation in an in vivo study, where usually a large amount is needed for a 
tested inhibitor (Chang, 2009). 
 
Fig. 1. Some tyrosinase inhibitors. 
To treat hyperpigmentation through chemical treatments or bleaching creams are used. 
Most of the inhibitors are phenol or catechol derivatives, structurally similar to tyrosine or 
DOPA (Briganti, 2003). Hydroquinone (Fig. 1), a widely used skin lightening agent, is 
probably the most used bleaching cream on the market but it has a laundry list of warnings, 
including risk of hepatotoxicity. However, it is the most widely used bleaching cream in the 
world, despite the potential health side effects. It is also a reliable treatment for melasma. 
Kojic acid is used as an antioxidant and alternative to hydroquinone for skin lightening by 
the cosmetic industry (Gupta, 2006).  
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Although the huge number of reversible inhibitors has been identified, rarely irreversible 
inhibitors of tyrosinase have been found until now. Captopril, used as an antihypertensive 
drug, is able to prevent melanin formation as a good example of irreversible inhibitors 
(Khan, 2007). Another example for tyrosinase inhibitor azelaic acid, has anti-inflammatory, 
antibacterial, and antikeratinizing effects, which make it useful in a variety of dermatologic 
conditions (Briganti, 2003; Gupta, 2006). Besides, 4,4′-biphenyl derivative exhibited strong 
tyrosinase inhibitory activity and also assessed for the melanin biosynthesis in B16 
melanoma cells (Kim, 2005). 
2. Kojic acid 
Kojic acid, the most intensively studied inhibitor of tyrosinase, was discovered by K. Saito in 
1907. Since the early twentieth century, it has been known as an additive to prevent 
browning of food materials such as crab, shrimp, and fresh vegetables in food industry (e.g., 
as an antioxidant or antibrowning agent) in order to preserve their freshness and to inhibit 
discoloration. It shows a competitive inhibitory effect on monophenolase activity and a 
mixed inhibitory effect on the diphenolase activity of mushroom tyrosinase. The ability of 
kojic acid to chelate copper at the active site of the enzyme may well explain the observed 
competitive inhibitory effect. In addition, it is reported to be a slow-binding inhibitor of the 
diphenolase activity of tyrosinase (Cabanes, 1994). It is a biologically important natural 
antibiotic produced by various fungal or bacterial strains such as Aspergillus oryzae, 
Penicillium or Acetobacter spp. in an aerobic process from a wide range of carbon sources 
(Bentley, 2006; Brtko, 2004; Burdock, 2001). It plays an important role in iron-overload 
diseases such as β-thalassemia or anemia, since it possesses iron chelating activity (Brtko, 
2004; Moggia, 2006; Stenson, 2007; Sudhir, 2005; Zborowski, 2003). Also, it forms stable 
complexes of metal kojates via reaction of kojic acid with metal acetate salts such as tin, 
beryllium, zinc, copper, nickel, cobalt, iron, manganese, chromium, gold, palladium, 
indium, gallium, vanadium, and aluminium (Fig. 2) (Barret, 2001; Cecconi, 2002; Emami, 
2007; Finnegan, 1987; Hryniewicz, 2009; Masoud, 1989; Moggia, 2006; Naik, 1979; Sudhir, 
2005; Yang, 2008; Zaremba, 2007; Zborowski, 2005). They were used as new drugs in the 
therapy of some diseases such as diabetes, anemia, fungal infections and neoplasia (Brtko, 
2004; Song, 2002; Wolf, 1950). Tris(kojic acid) aluminium(III) and -gallium(III) complexes 
have lipid solubility; therefore, they can cross the blood-brain barrier with considerable 
facility (Finnegan, 1987).  
 
Fig. 2. M(Kojic acid)n (n=2,3) metal complexes.  
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Kojic acid has weaker activity than ethylmaltol (2-ethyl-3-hydroxy-4H-pyran-4-one) against 
the convulsions induced by pentetrazole and strychnine. It is generally accepted that the 
lipid solubility of a drug is an important factor in connection with its transfer into the central 
spinal fluid and brain. The increase of inhibitory effect of 2-alkyl-3-hydroxy-4H-pyran-4-
ones on the pentetrazole-induced convulsion with increasing carbon number of the alkyl 
group might be due to the  enhancement of lipid solubility (Aoyagi, 1974; Kimura, 1980).  
In acute, chronic, reproductive and genotoxicity studies, kojic acid was not found as a 
toxicant. Due to slow absorption into the circulation from human skin, it would not reach 
the threshold at tumor promotion and weak carcinogenicity effects were seen. The Cosmetic 
Ingredient Review (CIR) Expert Panel concluded that it is safe for use in cosmetic products 
up to a concentration level of 1%. The available human sensitization data support the safety 
of kojic acid at a concentration of 2% in leave-on cosmetics, suggesting that a limit of 2% 
might be appropriate. In an industrial survey of current use concentrations, it is used at 
concentrations ranging from 0.1% to 2%. The European Commission’s Scientific Committee 
on Consumer Products (SCCP) determined that, based on a margin of safety calculation, the 
use of kojic acid at a maximum concentration of 1.0% in skin care formulations poses a risk 
to human health due to potential systemic effects (thyroid side effects). The SCCP also found 
it to be a potential skin sensitizer (Burnett, 2011). 
2.1 Kojic acid as a tyrosinase inhibitor 
It is well recognized that kojic acid, of high purity (99%) made by a certain pharmaceutical 
manufacture, began to be used extensively as a cosmetic skin-whitening product (quasi-
drug) especially in Japan, for topical application. Because of its slow and effective reversible 
competitive inhibition of human melanocyte tyrosinase, kojic acid prevents melanin 
formation. So, it can play an important role at the formation of cellular melanins (Cabanes, 
1994; Jun, 2007; Kahn, 1997; Kang, 2009; Kim, 2003; Lin, 2007; Noh, 2007; Raku, 2003; Saruno, 
1979). Noncosmetic uses reported for kojic acid include therapeutic uses for melasma, 
antioxidant and preservative in foods, antibiotic, chemical intermediate, metal chelate, 
pesticide, and antimicrobial agents. Because of its well-documented ability to inhibit 
tyrosinase activity, kojic acid has been used in numerous studies as a positive control. It was 
showed that kojic acid have inhibitory effect on mushroom, plant (potato and apple), and 
crustacean (white shrimp, grass prawn, and Florida spiny lobster) tyrosinase. The inhibition 
mushroom, potato, apple, white shrimp and spiny lobster tyrosinase was found to be 
related with the kojic acid inhibited melanosis by interfering with the uptake of O2 required 
for enzymatic browning (Chen, 1991). It was well-known that tyrosinase containing two 
copper ions in the active center and a lipophilic long-narrow gorge near to the active center. 
It has been reported that kojic acid inhibits the activity of tyrosinase by forming a chelate 
with the copper ion in the tyrosinase through the 5-hydroxyl and 4-carbonyl groups. There 
are several types of assays determining tyrosinase inhibition. Cabanes et al. stated that kojic 
acid is a slow-binding inhibitor of catecholase activity of frog tyrosinase in a nonclassical 
manner (Cabanes, 1994). In a study of several mammalian melanocyte tyrosinase inhibitors, 
kojic acid was considered a potent free enzyme inhibitor (Curto, 1999). Kojic acid was a 
positive control in a study of the inhibitory effects of oxyresveratrol and hydroxystilbene 
compounds on mushroom and murine melanoma B-16 tyrosinase (Kim, 2002). Melanoma-
specific anticarcinogenic activity is also known to be linked with tyrosinase activity (Kim, 
2005). Malignant melanoma continues to be a serious clinical problem with a high mortality 
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rate among the human beings (Seo, 2003). Therefore, the potential therapies targeting 
tyrosinase activity have a paramount importance. 
The beauty industry agrees with the statement regarding kojic acid is one of the best natural 
based lotions as far as skin lightening agents go. The definition of beauty for some cultures 
consists of fair, even toned skin, so many women resort to using skin lightening products, 
such as kojic acid, to achieve a lighter skin tone. It has been used for years in the Far East as 
an alternative to hydroquinone for its bleaching effects but many women are using it to treat 
hyperpigmentation as well as sun spots, freckles, liver spots and a number of other pigment 
problems related to beauty. The majority of lightening lotions contains a healthy dose of 
kojic acid in it beside vitamin C (ascorbic acid), bearberry extract, licorice or mulberry; in 
some cases, kojic acid is the main active ingredient. Most skin lightening lotions that use 
kojic acid as one of their ingredients also use small amounts of hydroquinone as well as 
glycolic acid (Fig. 1).  
In addition, kojic acid is found to prevent photodamage and subsequent wrinkling of the 
skin in the hairless mouse. It is a good chelator of transition metal ions and a good 
scavenger of free radicals therefore it is an effective agent for photoprotection (Mitani, 2001). 
Also, it is used as bleaching agent in cosmetics (Burdock, 2001; Lin, 2007). Current evidence 
suggests that it induces skin depigmentation through suppression of free tyrosinase, mainly 
due to chelation of its copper at the active site of the enzyme (Chen, 1991; Jun, 2007; Lee, 
2006).  It has been demonstrated to be responsible for therapy and prevention of 
pigmentation, both in vitro and in vivo and being used for topical application. Melasma is 
often affecting women, especially those living in areas of intense UV radiation. In treatment 
of melasma which continues to be a difficult problem, the addition of kojic acid in a gel 
containing glycolic acid and hydroquinone improved melasma. Kojic acid is found as 
effective as hydroquinone in reducing the pigment. The combination of both agents 
augments this inhibition further (Gupta, 2006). 
Previous antimicrobial activity studies showed that kojic acid was more active against gram 
negative bacteria than against gram positive ones (Bentley, 2006). However, some of its 
derivatives have shown adverse effects different from kojic acid’s antibacterial activity 
results (Aytemir, 2003a, 2003b; Fassihi, 2008; Kotani, 1978; Masoud, 1989; Petrola, 1985; 
Veverka, 1992). Also, its derivatives especially have significant antifungal activity against C. 
albicans and C. krusei (Aytemir, 2003b, 2004; Brtko, 2004; Fassihi, 2008; Kayahara, 1990; 
Mitani, 2001; Veverka, 1992). According to its antibacterial and fungicidal properties, kojic 
acid is used as a food additive (Burdock, 2001). There are several forms of kojic acid 
containing products including soap, cream, lotion and gel. Kojic acid also has antifungal and 
antibacterial properties in it, making it a perfect ingredient to be used in soap. Women who 
choose a kojic acid lotion tend to use it to treat smaller areas of the skin that have been 
affected by hyperpigmentation, age spots or hormone related skin conditions brought on by 
pregnancy or birth control pills. Some women favor this lotion because it absorbs directly 
into the skin much better than creams or soaps. One of the greatest benefits to using kojic 
acid is reduction of getting wrinkles when you use the lotion before exposure to the sun. So 
it makes this also a perfect anti-aging lotion. Based on such tyrosinase-inhibiting activity of 
kojic acid, there have been proposed a lot of cosmetic compositions containing kojic acid as 
an active ingredient. There are a variety of kojic acid creams available for purchase online 
and in certain specialty stores. Each one has its own unique blend of ingredients which set 
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them apart from one another. Some creams combine various vitamins like A and E which 
give them different effects. The reason many people mix these vitamins within the kojic acid 
creams is to help them alleviate the skin irritation that has been said to occur with kojic acid 
products. Another cream combines retinol, vitamin C, with kojic acid, and glycolic acid. 
These ingredients are added to this base to help counteract the sensitivity that is associated 
with prolonged use of kojic acid when it is used by itself. According to FDA kojic acid is 
used in a total of 16 products. Some of the trade names of kojic acid having skin-whitening 
usage are AEC Kojic acid, Kojic acid SL, Melanobleach-K, Oristar KA, Rita KA and Tonelite 
Kojic acid. Besides these there are trade name mixtures in markets Botacenta SLC 175, 
Dermawhite HS, Melarrest A, Melarrest L and Vegewhite (Burnett, 2011; FDA, 2009).  
The development of tyrosinase inhibitors is of great concern in the medical, agricultural, and 
cosmetic fields. Among the many kinds of tyrosinase inhibitors, kojic acid has been 
intensively studied. It acts as a good chelator of transition metal ions such as Cu2+ and Fe3+ 
and a scavenger of free radicals. This fungal metabolite is currently applied as a cosmetic 
skin-lightening agent and food additive to prevent enzymatic browning. Kojic acid shows a 
competitive inhibitory effect on the monophenolase activity and a mixed inhibitory effect on 
the diphenolase activity of mushroom tyrosinase. However, its use in cosmetics has been 
limited, because of the skin irritation caused by its cytotoxicity and its instability during 
storage. Accordingly, many semi-synthetic kojic acid derivatives have been synthesized to 
improve its properties by converting the alcoholic hydroxyl group into an ester, 
hydroxyphenyl ether, glycoside, amino acid derivatives, or tripeptide derivatives (Kang, 
2009; Lee, 2006).  
2.2 Some studies on synthetic kojic acid derivatives 
Recently, it was found that kojic acid-tripeptide amides showed similar tyrosinase inhibitory 
activities to those of kojic acid-tripeptide free acids but exhibited superior storage stability 
than those of kojic acid and kojic acid-tripeptide free acids (Noh, 2007). To find further kojic 
acid derivatives with higher tyrosinase inhibitory activity, stability, and synthetic efficiency, 
a library of kojic acid-amino acid amides (KA-AA-NH2) prepared and screened for their 
tyrosinase inhibitory activities. It was also confirmed that the kojic acid-phenylalanine 
amides reduced the amount of dopachrome production during the melanin formation. It 
was suggested that a tyrosinase inhibition mechanism of KA-AA-NH2 based on the possible 
hydrophobic interactions between the side chain of KA-AA-NH2 and tyrosinase active site 
by a docking program (Noh, 2009; Kim, 2004). 
Kojic acid is a potential inhibitor of NF-κB(transcription factor) activation in human 
keratinocytes, and suggests the hypothesis that NF-κB activation may be involved in kojic 
acid induced anti-melanogenic effect. It was reported that the inhibitory effect of kojic acid 
on the activation of NF-κB in two human keratinocytes and suggest the hypothesis that the 
modulation of NF-κB in keratinocytes may be involved in anti-melanogenic effect induced 
by kojic acid (Moon, 2001). 
The metal complexes of kojic acid-phenylalanine-amide exhibited potent tyrosinase 
inhibitory activity both in vitro enzyme test and in cell-based assay system. These results 
demonstrated that metal complex formation could be applied as a delivery system for 
hydrophilic molecules which have low cell permeability into cells. In addition, these new 
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materials can be used as an effective whitening agent in the cosmetic industry or applied on 
irregular hyperpigmentation (Kwak, 2010). Furthermore, kojic acid was shown to inhibit 
different enzymes relevant to the undesirable melanosis of agricultural products, which is 
related to its coordination ability to, e.g., copper, in the active site of tyrosinase (Naik, 1979; 
Stenson, 2007; Synytsya, 2008). The kojic acid scaffold was modified by a Mannich reaction 
with piperidine derivatives with the aim to link it to Ru(II)–arene fragments and to obtain 
compounds with anticancer activity (Kasser, 2010). 
 
Fig. 3. Chemical structure of some synthetic kojic acid derivatives as tyrosinase inhibitors. 
It was reported that compound, joining to two pyrone rings of kojic acid through an 
ethylene linkage, exhibited 8 times more potent mushroom tyrosinase inhibitory activity 
than that of kojic acid and also showed superior melanin synthesis inhibitory activity using 
B16F10 melanoma cell (Lee, 2006). A series of kojic acid derivatives containing thioether, 
sulfoxide and sulfone linkages were synthesized. Sulfoxide and sulfone derivatives 
decreased and kojyl thioether derivatives containing appropriate lipophilic various alkyl 
chains increased tyrosinase inhibitory activity (Rho, 2010). Kojic acid derivatives, containing 
ester linkages such as hydrophobic benzoate or cinnamate groups, increased the inhibitory 
activity of kojic acid. When the enolic hydroxyl group of ester derivatives was protected by 
a methyl group the activity was lost completely. These results indicated that the kojic acid 
moiety may have blocked the copper active site of tyrosinase (Rho, 2011). 5-[(3-
aminopropyl)phosphinooxyl]-2-(hydroxymethyl-4H-pyran-4-one (Kojyl-APPA) was 
showed tyrosinase inhibition effect in situ, but not in vitro. It means that Kojyl-APPA was 
converted to kojic acid and 3-aminopropane phosphoric acid enzymatically in cells. Kojyl-
APPA was showed the inhibitory activity to same extent as kojic acid on melanin synthesis 
in mouse melanoma and normal human melanocytes (Kim, 2003). 
In a recent study, the correlations of the inhibition of cell-free mushroom tyrosinase activity 
with that of cellular tyrosinase activity and melanin formation in A2058 melanoma cell line 
using kojic acid were evaluated. Kojic acid (10 μM) exhibited the best inhibitory effects  
with % inhibition values 33.3, 52.7 and 52.5 respectively against mushroom tyrosinase 
activity, cellular tyrosinase activity and cellular melanin formation. Also, ultraviolet A 
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irradiation of melanoma cells A2058 markedly improved the correlation between the 
inhibition of cellular tyrosinase and of melanin formation (Song, 2009). 
Kojic acid contains a polyfunctional heterocyclic, oxygen containing ring with several 
important centers enabling additional reactions like as oxidation and reduction, alkylation 
and acylation, substitution nucleophilic reactions, substitution electrophilic reactions, a ring 
opening of the molecule, and chelation (Aytemir, 1999; Brtko, 2004; Dehkordi, 2008; O’Brien, 
1960; Pace, 2004). Since kojic acid is freely soluble in water, ethanol, acetone, and sparingly 
soluble in ether, ethylacetate, and chloroform, its various derivatives were advantageously 
prepared (Brtko, 2004; Burdock, 2001; Krivankova, 1992). 
Kojic acid provides a promising skeleton for development of new more potent derivatives 
such as chlorokojic acid (2-chloromethyl-5-hydroxy-4H-pyran-4-one), allomaltol (5-hydroxy-
2-methyl-4H-pyran-4-one) and pyromeconic acid (3-hydroxy-4H-pyran-4-one) (Fig. 4). 
Allomaltol was synthesized from commercially available kojic acid in a two-step reaction 
according to the literature (Aytemir, 2004; 2010a; 2010b). Chlorination of the 2-
hydroxymethyl moiety of kojic acid using thionyl chloride at room temperature afforded 
chlorokojic acid, with the ring hydroxyl being unaffected. Reduction of chlorokojic acid with 
zinc dust in concentrated hydrochloric acid resulted in the production of allomaltol  
(Scheme 2) (Aytemir, 2004; 2010a; 2010b; Ellis 1996). 
 
 
Fig. 4. Hydroxypyranone derivatives. 
 
 
Scheme 2. Synthesis of some hydroxypyrone derivatives from kojic acid. 
Wolf and Westveer showed that chlorokojic acid contains catechol group-inhibited 
Aeromonas aerogenes, Micrococcus pyogenes var. aureus, Salmonella typhosa, Penicilium digitalum, 
Russula nigricans and Saccharomyces cerevisiae (Wolf, 1950). Also, chlorokojic acid and other 
halogen derivatives have significant antifungal activity. Moreover, their copper(II) salts’ 
complex derivatives were prepared and found to be more active than chlorokojic acid 
(Brtko, 2004). Chlorokojic acid was found to be more potent inhibitor of tyrosinase than kojic 
acid. Moreover, allomaltol has been described as a treatment for pigmentation disorders, 
sunburn prevention and as an antioxidant for oils and fats (Wempe, 2009). Ester derivatives 
of allomaltol were described as new tyrosinase inhibitors. 
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It is well known that hydroxypyranones can exist in cationic and anionic forms due to the 
protonation or deprotonation reactions, respectively. The hydroxyl group that is directly 
bound to the pyranone ring was probable more deprotonated than the hydroxymethyl 
group. The results of quantum mechanical investigations on tautomeric equilibria of kojic 
acid were determined. Because of two intramolecular hydrogen bonds, the enolic structure 
of neutral kojic acid is expected to be the most stable one. One of these two bonds is located 
between keto and hydroxyl group and the other hydrogen bond can be formed weakly 
between hydroxymethyl moiety and intra-ring oxygen (Beelik, 1955). 
On the other hand, kojic acid and other hydroxypyranones having catechol groups are also 
known as effective metal chelation agents which form complexes with various metal ions 
that are potentially useful in medicinal therapy. These complexes have reasonable 
hydrolytic stability, neutral charge, and significant lipophilicity (Masoud, 1989; Thompson, 
2001). Additionally, kojic acid and its derivatives have shown to possess various 
pharmacological activities such as herbicidal (Veverka, 1990; 1990), anti-speck (Uchino, 
1988), pesticide and insecticide (Higa, 2007; Kahn, 1997; Uher, 1994), antitumor (Uher, 1994; 
Yamato, 1987), anti-diabetes (Xiong, 2008), slight anti-inflammatory effects (Brtko, 2004), 
antiproliferative properties (Fickova, 2008) antiepileptic (Aytemir, 2004, 2006, 2007, 2010a, 
2010b) and antiviral (Aytemir, 2010c, 2011) activity. 
3. Mannich derivatives with biological activities 
Multicomponent reactions are the major parts of the synthetic organic chemistry with 
advantages ranging from lower reaction times and temperatures to higher yields. Mannich-
type reactions are a three component condensation reaction involving carbonyl compounds, 
which exist as keto-enol tautomeric forms, formaline and a primary or secondary amine. 
Due to phenol-like properties of kojic acid readily undergoes aminomethylation in the 
Mannich reaction ortho to enolic hydroxyl group at room temperature. It was reported that 
di-Mannich derivatives which were formed at 3- and 6-positions, were obtained in an acidic 
medium by the reaction of kojic acid, formaline and aromatic amine derivatives. Woods has 
reported di-Mannich derivatives were obtained in an acidic medium from kojic acid, 
formaline and aromatic amine (Woods, 1946). However, O’Brien et al. showed that 
derivatives of Mannich bases occurred at only 6-position of kojic acid, which were 
synthesized using dimethylamine, diethylamine, pyrrolidine, morpholine, piperidine or 4-
methylpiperazine, and chlorokojic acid. Additionally, 6-morpholino or piperidinomethyl 
chlorokojic acid were prepared via Mannich reaction (O’Brien, 1960). At the latter study, 
Mannich bases of kojic acid and pyromeconic acid were synthesized in either acidic and 
basic medium using aliphatic or heterocyclic secondary amines such as dimethylamine, 
diethylamine or morpholine, respectively (Ichimoto, 1965).  
Using the methodology shown in Scheme 3, having 6-chloromethyl/hydroxymethyl/methyl-
3-hydroxy-2-substituted 4H-pyran-4-one structure, 130 derivatives were synthesized as 
Mannich bases. The basic substituent was introduced in the 6-position of 
allomaltol/chlorokojic acid/kojic acid via a Mannich-type reaction, using formaline and an 
appropriate substituted piperidine, piperazine and morpholine derivatives in methanol at 
room temperature (Scheme 3). The reaction proceeded very rapidly (Aytemir, 2004, 2006, 2007, 
2010a, 2010b, 2010c, 2011 and unpublished data). 
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Scheme 3. Synthesis of Mannich bases of kojic acid/chlorokojic acid/allomaltol. 
Structure of some Mannich bases was determined by X-Ray analysis. The conformation of 
the molecule is determined by intra- and intermolecular hydrogen bonds. Some weak 
intramolecular interactions helped to stabilize the structure. The piperazine ring displayed 
an almost perfect chair conformation (İskeleli, 2005; Köysal, 2004; Ocak, 2004). 
3.1 Anticonvulsant activity 
In our previous studies, we reported that Mannich bases of 3-hydroxy-6-
hydroxymethyl/methyl-2-substituted 4H-pyran-4-one derivatives anticonvulsant activity 
(Aytemir, 2004, 2006, 2007, 2010a, 2010b). Anticonvulsant activity was examined by maximal 
electroshock (MES) and subcutaneous Pentylenetetrazol (scPTZ)-induced seizure tests. 
Substitution of different lipophilic phenyl derivatives at 4th position of piperazine ring 
enables penetration of the blood-brain barrier. The effects of mono substitution of an 
electron donating or electron-withdrawing groups at the ortho, meta and para position of 
the phenyl group were examined. According to the results, these compounds, especially 4-
chlorophenyl and 3-trifluoromethylphenylpiperazine derivatives, had valuable 
anticonvulsant activity against scPTZ and MES induced seizure tests (Aytemir, 2004). When 
substituted piperidine derivatives and morpholine ring at 2nd positions of allomaltol (Fig. 1) 
were used instead of piperazine ring, anticonvulsant activity of these Mannich bases 
derivatives was decreased (Aytemir, 2007, 2010a). Both kojic acid and allomaltol derivatives 
including 4-chloro and 3-trifluoromethylphenylpiperazine were determined to be protective 
against all seizures. When the effect of different piperazine ring upon activity examined, 
kojic acid derivatives were found to be more active than allomaltol derivatives. The 
difference between these two starting materials is just methyl or hydroxymethyl groups at 
6th positions at pyranone ring. On the other hand, when the results of the studies are 
compared to each other, replacement of hydroxymethyl with methyl group at 6th position at 
pyranone ring increases the protective effect against both tests, because of two hydrogen 
bonds of kojic acid, which are located between keto and hydroxyl group and/or 
hydroxymethyl moiety and intra-ring oxygen (Aytemir, 2010b). 
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R R’ 
MES scPTZ 
0.5 h (mg/kg) 4 h (mg/kg) 0.5 h (mg/kg) 4 h (mg/kg) 
-CH3 
 
30 300 - 300 
-CH3 
 
- 300 300 30 
-CH3 
 
300 30 30 - 
-CH3 
 
100 300 30 - 
-CH3 
 
100 30 - 30 
-CH2OH 
 
300 - 30 30 
-CH2OH 
 
300 - - 30 
-CH2OH 
 
- - - 30 
-CH2OH 
 
- 30 100 300 
-CH2OH 
 
- 300 30 100 
-CH2OH 
 
- - 30 30 
-CH2OH 
 
300 - 300 30 
-CH2OH 
 
30 30 100 300 
-CH2OH 
 
30 300 - - 
Table 1. Anticonvulsant activities of the synthesized compounds. 
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3.2 Antiviral activity  
All compounds were assayed against both herpes simplex virus-1 (HSV-1) and human 
parainfluenza virus type 3 (PI-3) by using Madin Darby Bovine Kidney and Vero cell lines 
with the aim to capture structure relationship in each of the compounds. Acyclovir and 
oseltamivir were used as control agents. Correlation between toxicity on uninfected cells 
(Vero, MDBK) and antiviral activity of the synthesis compounds were determined in the 
same microtiter plate. The results of the antiviral study are presented in Table 2. 
 
 
MDBK Cells Vero Cells 
 R 
MNTCs a) 
(µg/mL) 
CPE b) Inhibitory 
Concentration HSV-1 c) MNTCs
 a) 
(µg/mL) 
CPE b)  
Inhibitory 
Concentration 
PI-3 d) 
Max. Min. Max. Min. 
1 
 
0.8 0.8 0.05 0.8 0.4 0.025 
2 
 
0.8 0.8 0.05 0.4 0.4 0.025 
3 
 
0.8 0.8 0.05 0.8 0.2 0.025 
4 
 
0.8 0.8 0.05 1.6 0.2 0.025 
5 
 
0.8 0.8 0.2 1.6 0.2 0.05 
6 
 
0.8 0.8 0.2 1.6 0.4 0.1 
7 
 
1.6 1.6 0.1 1.6 0.8 0.05 
8 
 
1.6 0.4 0.1 0.4 0.4 0.2 
9 
 
1.6 0.8 0.1 0.8 0.8 0.025 
10 
 
1.6 0.4 0.1 0.4 0.4 0.025 
11 
 
1.6 0.4 0.1 0.4 0.4 0.05 
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MDBK Cells Vero Cells 
 R 
MNTCs a) 
(µg/mL) 
CPE b) Inhibitory 
Concentration HSV-1 c) MNTCs
 a) 
(µg/mL) 
CPE b)  
Inhibitory 
Concentration 
PI-3 d) 
Max. Min. Max. Min. 
12 
 
1.6 0.4 0.1 0.4 0.4 0.05 
13 0.4 - - 0.8 0.8 0.05 
14 
 
0.4 - - 0.4 0.2 0.1 
15 
 
0.8 0.8 0.4 0.4 0.4 0.2 
16 
 
0.4 - - 0.8 0.2 0.05 
17 
 
0.8 0.8 0.2 0.4 0.2 0.05 
18 
 
0.4 - - 0.4 0.4 0.05 
Acyclovir 1.6 1.6 <0.012    
Oseltamivir - - - 1.6 1.6 <0.012 
a) MNTCs:  Maximum non-toxic concentrations  
b) CPE: Cytopathogenic effect  
c) HSV-1: Herpes simplex virus Type-1 
d)PI-3: Parainfluenza-3 virus Max: Maximum 
Min: Minimum - : Not done; activity observed 
Table 2. Cytotoxicity on MDBK and Vero Cells as well as antiviral activity against HSV-1 
and PI-3 results of the compounds 1-18. 
As given in CPE inhibitory concentration ranging, compound 7 bearing 4-
methoxyphenylpiperazine substituent showed significant activity against HSV-1 as potent 
as the reference compound acyclovir, but limited activity at maximum and minimum 
concentration ranges of 1.6-0.1 g/mL with the maximum non-toxic concentration 
(MNTCs) value of 1.6 g/mL. Additionally, compound 9 (0.8-0.1 g/mL) was shown anti-
Herpes simplex activity but less potent. On the other hand, compounds 1-4 were shown as 
same activity as compound 7 but on higher non-toxic concentrations (MNTC: 0.8 g/mL). 
Among the tested Mannich bases derivatives, compounds 5, 6, 8, 10, and 11 were less active 
against DNA virus. Take into account CPE inhibitory concentration ranging against the 
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RNA viruses PI-3, compound 9 (0.8-0.025 g/mL) and compound 13 (0.8-0.05 g/mL) had 
remarkable antiviral activity in Mannich base derivatives. Furthermore, compounds 1, 7, 12 
and 18 were less active than compounds 9 and 13. While the activities of compounds 2 and 
10 (0.4-0.025 g/mL) against PI-3 were in similar CPE inhibitory concentration range, 
compounds 3, 4 and 11 had lower activity than those had. Also, compounds 5 and 6 were 
negligible values as seen in Table 2.  Compounds 12 and 17 showed anti-Herpes simplex 
activity with less potency. While the activities of compounds 12 and 18 (0.4-0.05 g/mL) 
against PI-3 were in similar CPE inhibitory concentration range, compounds 5 and 6 had 
lower activity than those that had (Aytemir, 2010c, 2011). 
3.3 Antimicrobial activity 
The antibacterial and antifungal activity profiles of the newly synthesized compounds were 
assessed for antimicrobial activity against both standard and the isolated strains of bacteria. 
For antibacterial activity assessment, standard strains (Escherichia coli, Pseudomonas 
aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, Acinetobacter baumannii, Staphylococcus 
aureus, Enterococcus faecalis and Bacillus subtilis) and their drug-resistant isolates were tested; 
and for antifungal activity Candida albicans and C. parapsilosis were used. Ampicillin, 
vancomycin, gentamicin, ofloxacin, levofloxacin, ketoconazole, and fluconazole were also 
tested under identical conditions for comparison in antibacterial and antifungal assays, 
respectively. Tables 3 and 4 describe the in vitro antimicrobial activity with MIC values of 
compounds 1-18.  
According to our data (Table 3 and 4), the synthesized compounds showed a broad 
spectrum of activity against gram positive and gram negative standard strains with MIC 
values between 1 and 64 g/mL. In the meantime, the synthesized compounds showed 
activity against drug-resistant isolated both gram positive and negative strains with MIC 
values of 2 to ≥128 g/mL. 
As given in Table 3, the antibacterial activity against gram negative bacteria of  
the synthesized compounds 14, 16, and 17 bearing (4-chlorophenyl)benzylpiperazine,  
4-bromophenyl-4-hydroxypiperidine and 4-chloro-3-(trifluoromethyl) phenyl-4-
hydroxypiperidine moiety respectively at the 2-position of pyran-4-one ring, was found to 
have significantly high antibacterial potential against standard strains of E. coli, P. 
aeruginosa, K. pneumoniae, A. baumannii with a bacterial inhibition between 2 and 4 g/mL. 
Also, these compounds showed more activity (MIC: 2 g/mL) against E. coli and P. 
aeruginosa than the other gram negative bacteria compared with control drugs ampicillin 
(MIC: 2 g/mL), ofloxacin (1 g/mL) and levofloxacin (1 g/mL). As for compounds 13 
and 15, it was found that they had the same effect against all gram negative bacteria. The 
MIC values of both compounds were 4 g/mL against P. aeruginosa; 8 g/mL against E. coli, 
K. pneumoniae, and A. baumannii; and 16 g/mL against P. mirabilis. Furthermore, in 
comparison, compound 18 had similar antibacterial activity with MIC values between 4 and 
16 g/mL as these (compounds 13 and 15). In the entire series, compounds 1-7, 9, 12 was 
less effective (MIC: 16-32 g/mL) and compound 18 with MIC values between 4 and 16 
g/mL towards standard strains of all gram negative bacteria. Especially, compound 13 
which has 3,4-dichlorobenzylpiperazine moiety showed remarkable activity against ESǐL(+) 
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strains of E. coli and K. pneumoniae with MIC values of 4 g/mL, compared with the 
reference drugs, ampicillin (MIC: ≥128 g/mL), ofloxacin (MIC: 0.5 g/mL) and 
levofloxacin, (MIC: 0.5-1 g/mL) respectively. As for structure-activity relationship (SAR), 
fluoro substitution in para position of the benzyl ring (compound 12) has the worst activity 
with MIC values between 16 and 32 g/mL in this series, whereas the 3,4-dichloro 
substitution (compound 13) of benzyl ring increases antibacterial activity with four-folds 
(MIC: 4-8 g/mL) towards isolated strains of A. baumannii and P. aeruginosa and two-folds 
(MIC: 8 g/mL) against E. coli and K. pneumoniae. Moreover, antibacterial activity of the 
compounds 12 and 13 against P. mirabilis was determined to be the same. Furthermore, 
compounds 13 and 15 showed same activity against all bacteria except from P. aeruginosa. In 
the Mannich base derivatives bearing piperazine ring, compound 14 was the most 
remarkable and active one (MIC: 2-8 g/mL). There were diphenyl rings in the structure of 
in which  one of them was a p-chlorophenyl ring and the other a nonsubstituted phenyl 
ring. When compounds 13 and 15 were compared, the addition of phenyl ring on the 
structure of compound 14 increased the activity two-folds against all gram negative bacteria 
and S. aureus. When antibacterial activities of compounds 16-18 possessing piperidine ring 
were investigated, it was observed that compounds 16 and 17 were found to have the same 
activity and higher effect than compound 18 without halogen substitution at its structure. 
Hence, when hydroxy substitution at the 4-position of piperidine ring was changed with 
acetyl, antibacterial activity was decreased. In addition, there was no difference in the 
antimicrobial activity with the location and type of the halogen substituted on phenyl ring. 
Also, these compounds (16 and 17) had exactly the same activity as compound 18 possessing 
piperazine ring against all gram negative bacteria. 
Among gram positive bacteria, S. aureus has been recognized for so long as one of the 
major resistant pathogens that can cause diseases in humans. Likewise, multi-drug 
resistant Enterococci have become a serious threat for public health. High level resistance 
for penicillin and aminoglycosides are being reported of this bacterium. According to the 
obtained data (Table 4), antibacterial activity results of compounds 13-18 (MIC: 1-2 
g/mL) and 8-11 (MIC: 8 g/mL) against standard gram positive bacteria were 
encouraging, although compound 1-7 and 12 were found to manifest moderate (MIC: 16-
64 g/mL) activity against standard strains of S. aureus. Compounds 13-18 were found to 
be highly active against B. subtilis showing a bacterial inhibition value at 1 µg/mL. The 
antibacterial potential against E. faecalis was exhibited by compounds 2, 8-11, and 15 at 
concentration 8 g/mL among the synthesized compounds. Candida species are the most 
widespread and threatening fungal pathogens today, and are responsible for many of the 
invasive and non-invasive fungal infections. Among all Candida species, Candida albicans is 
the most frequent pathogen. The results obtained clearly indicate that the series of 
Mannich bases discussed here are active towards growth inhibition of pathogenic fungi. 
In general, 1-7 (MIC: 8 g/mL) and 13-18 (MIC: 4 g/mL) exhibited excellent antifungal 
activity against C. albicans and at MIC values at 8 g/mL against C. parapsilosis when 
compared to the reference drugs, ketoconazole (MIC: 1 g/mL) and fluconazole (MIC: 2-4 
g/mL). The compounds 1-7 and 13-18 may be promoted as fungicides. In general, the 
compounds showed an improved antibacterial activity when compared to their antifungal 
activity (Aytemir, 2010c, 2011). 
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Gram-negative Standard and Clinic Isolated Strains 
E. coli P. aeruginosa P. mirabilis K. pneumoniae A. baumannii 
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1 16 64 16 64 16 64 16 64 32 64 
2 16 64 16 64 16 64 32 64 16 64 
3 16 64 32 64 32 64 16 64 32 64 
4 16 64 32 64 16 64 16 64 32 64 
5 32 64 32 64 32 64 32 64 32 64 
6 32 64 32 64 32 64 32 64 32 64 
7 32 64 16 64 32 64 16 32 16 32 
8 64 >128 64 >128 64 >128 64 >128 64 >128 
9 32 64 32 64 32 64 32 64 32 64 
10 64 >128 64 >128 64 >128 64 >128 64 >128 
11 64 64 16 64 32 64 32 64 64 32 
12 16 64 16 64 16 64 16 64 32 64 
13 8 4 4 16 16 64 8 4 8 16 
14 4 64 2 16 8 64 4 64 4 16 
15 8 64 4 16 16 64 8 64 8 16 
16 4 64 2 16 8 64 4 64 4 16 
17 4 64 2 16 8 64 4 64 4 16 
18 8 64 4 16 16 64 8 64 4 16 
AMP a) 2 >128 - - 2 >128 2 >128 2 >128 
OFX b) 0.12 - 0.5 2 - - - - - - 
LVX c) <0.12 0.5 1 64 <0.12 1 <0.12 0.5 0.12 64 
a) AMP: ampicillin,  
b) OFX: ofloxacin,  
c) LVX: levofloxacin 
-: No activity observed, E. coli isolates; (resist to trimethoprim-sulfamethoxazole, cefepime, tazobactam), 
P. aeruginosa isolates (resist to Trimethoprim-Sulfamethoxazole, tazobactam), P.mirabilis isolates (resist 
to trimethoprim-sulfamethoxazole, cefepime, tazobactam), K. pneumoniae isolates (resist to 
trimethoprim-sulfamethoxazole, amoxicillin clavulonate, ceftriaxone, cefepime, aztreonam)  
A. baumannii isolates (resist to trimethoprim-sulfamethoxazole, cefepime). 
Table 3. Antibacterial activity of the synthesized compounds 1-18 and the control drugs 
(MIC in g/mL). 
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Comp. 
Gram-positive standard  and Clinic Isolated Strain 
Bacteria 
Fungi 
S. aureus E. faecalis B. subtilis C. albicans C. parapsilosis 
A
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C
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3 
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R
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22
01
9 
1 32 64 16 32 32 64 8 8 
2 16 64 8 32 8 64 8 8 
3 16 64 16 32 8 16 8 8 
4 16 64 16 32 16 32 8 8 
5 64 128 64 128 16 32 8 8 
6 64 128 64 128 16 32 8 8 
7 32 64 32 64 32 64 8 8 
8 8 >128 8 >128 16 >128 16 16 
9 8 128 8 128 16 32 16 16 
10 8 >128 8 >128 16 >128 16 16 
11 8 64 8 64 16 64 16 16 
12 32 64 16 32 32 64 16 16 
13 2 128 16 128 1 2 4 8 
14 1 64 16 32 1 2 4 8 
15 2 128 8 128 1 2 4 8 
16 1 64 16 32 1 2 4 8 
17 1 64 16 32 1 2 4 8 
18 2 128 64 128 1 2 4 8 
AMPa) <0.12 >128 0.5 >128 0.12 0.5 - - 
VAN b) 0.12 2 - - - - - - 
OFX c) 0.25 64 1 32 - - - - 
LVX d) 0.25 128 0.5 32 - - - - 
KET e) - - - - - - 1 1 
FLU f) - - - - - - 2 4 
a) AMP: ampicillin,  
b) VAN: vancomycin,  
c) OFX: ofloxacin,  
d) LVX: levofloxacin,  
e) KET; ketoconazole,   
f) FLU: fluconazole 
-: No activity observed, S. aureus isolates (resist to oxacillin, gentamicin, aztreonam, trimethoprim-
sulfamethoxazole), E. faecalis isolates (resist to cephalosporins & beta-lactam), B. subtilis isolates (resist 
to ceftriaxone). 
Table 4. Antibacterial and antifungal activities of the synthesized compounds 1-18 and the 
control drugs (MIC in g/mL).  
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4. Conclusions 
A number of research groups around the world are engaged and are expending much effort 
in the discovery of tyrosinase inhibitors. Various limitations are associated with many of 
these inhibitors, such as high cytotoxicity, poor skin penetration and low stability in 
formulations. Therefore, it is very important to discover novel and potent inhibitors with 
potent activity and lower side effect. 
Kojic acid is currently used as tyrosinase inhibitors which are commercially available. 
Unfortunately, unstability during storage limits its use  and new tyrosinase inhibitors of 
novel kojic acid derivatives are needed in cosmetics industry. More expended studies on 
this subject will be helpful in designing more suitable tyrosinase inhibitors for human use. 
In our continuing search, a huge number of Mannich bases are being examined as inhibiting 
mushroom tyrosinase activity at the moment, and few of them will have confirmed in 
melanogenesis inhibiting activity in cell or skin models. Mannich bases compounds are 
more hydrophobic than kojic acid. Therefore, disadvantages of kojic acid might be 
decreased by increasing skin penetration and stability in formulation. In the light of these 
findings we will undertake further synthetic and biological studies on the new compounds 
in the future. 
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